Microsaic Systems plc Research agreement with global biopharma partner (1543Z)
December 13 2017 - 1:00AM
UK Regulatory
TIDMMSYS
RNS Number : 1543Z
Microsaic Systems plc
13 December 2017
13 December 2017
Microsaic Systems plc
("Microsaic" or the "Company")
Microsaic signs new phase of research agreement with a global
partner in biopharma
Microsaic Systems plc (AIM: MSYS), the developer of chip-based
mass spectrometry instruments, announces that it has signed a
research agreement extending its collaboration with a long standing
global partner in the scale up and manufacture of biopharmaceutical
drugs. This amendment to the agreement has been entered into
following the successful completion of a collaboration stage
contracted in a previous amendment announced on 7 April 2017.
Glenn Tracey, CEO of Microsaic Systems plc, commented: "We are
delighted to agree this new phase of our collaboration with one of
the foremost players in the global market for scientific
instrumentation, which is in line with the Company's strategy to
focus on application areas in bioprocessing and diagnostics. Since
our previous announcement in April, in cooperation with the
partner, we have demonstrated the technical feasibility of a
specific biopharma application, and established the interest of end
users. In this most recent contracted phase, which is expected to
last into H2 2018, we will work closely with the partner to further
integrate our MS technology with their world leading purification
equipment. Our goal is that this will be followed by full product
development and launch. If this goal is realised, we estimate that
this product alone will represent a major commercial opportunity
for Microsaic. Additionally, we will be evaluating other potential
applications with this partner.
"I am pleased that with this extension and deepening of our
collaboration, our partner is demonstrating confidence both in
Microsaic's MS technology, and in the potential of miniature MS in
the bioprocessing industry."
This announcement is released by Microsaic Systems plc and
contains inside information for the purposes of Article 7 of the
Market Abuse Regulation (EU) 596/2014 ("MAR"), encompassing
information relating to the agreement described herein, and is
disclosed in accordance with the Company's obligations under
Article 17 of MAR.
For the purposes of MAR and Article 2 of Commission Implementing
Regulation (EU) 2016/1055, this announcement is being made on
behalf of the Company by Glenn Tracey, CEO.
For more information, please contact:
Microsaic Systems plc
Glenn Tracey, CEO +44 (0) 1483
Bevan Metcalf, FD 751577
N+1 Singer (Nominated Adviser
& Broker)
Shaun Dobson +44 (0)20 7496
Liz Yong 3000
IFC Advisory (Financial PR)
Graham Herring
Heather Armstrong +44 (0)20 3934
Florence Chandler 6630
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRKLLFFDLFZFBB
(END) Dow Jones Newswires
December 13, 2017 02:00 ET (07:00 GMT)
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From Apr 2024 to May 2024
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From May 2023 to May 2024